2023
DOI: 10.3389/fncel.2023.1292858
|View full text |Cite
|
Sign up to set email alerts
|

Targeting dopamine transporter to ameliorate cognitive deficits in Alzheimer's disease

Ammara Shaikh,
Fairus Ahmad,
Seong Lin Teoh
et al.

Abstract: Alzheimer's disease (AD) is characterized by the pathologic deposition of amyloid and neurofibrillary tangles in the brain, leading to neuronal damage and defective synapses. These changes manifest as abnormalities in cognition and behavior. The functional deficits are also attributed to abnormalities in multiple neurotransmitter systems contributing to neuronal dysfunction. One such important system is the dopaminergic system. It plays a crucial role in modulating movement, cognition, and behavior while conne… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 102 publications
0
1
0
Order By: Relevance
“…Dopamine elevation in the brain has been suggested as an alternative to ameliorate cognitive deficits observed in Alzheimer's disease ( Ambree et al, 2009 ; Shaikh et al, 2023 ). However, in the context of Parkinson's disease it is known that the global elevation of dopamine in the brain by the use of dopaminergic agonists produces nondesired side effects such as ʟ-DOPA induced dyskinesias, hallucinations, and compulsive behaviors ( Talati et al, 2009 ; Voon et al, 2011 ; Blandini and Armentero, 2014 ), highlighting the need of pharmacological tools that allow the temporal and spatial control of dopamine release.…”
Section: Introductionmentioning
confidence: 99%
“…Dopamine elevation in the brain has been suggested as an alternative to ameliorate cognitive deficits observed in Alzheimer's disease ( Ambree et al, 2009 ; Shaikh et al, 2023 ). However, in the context of Parkinson's disease it is known that the global elevation of dopamine in the brain by the use of dopaminergic agonists produces nondesired side effects such as ʟ-DOPA induced dyskinesias, hallucinations, and compulsive behaviors ( Talati et al, 2009 ; Voon et al, 2011 ; Blandini and Armentero, 2014 ), highlighting the need of pharmacological tools that allow the temporal and spatial control of dopamine release.…”
Section: Introductionmentioning
confidence: 99%